EV-302: Patient-Reported Outcomes from EV+Pembro in mUC
June 20th 2024Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer
June 17th 2024Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.
Recent Updates from MARIPOSA on Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC
June 11th 2024Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.
LAURA: Osimertinib after Definitive CRT in Unresectable Stage III NSCLC with EGFR Mutations
June 11th 2024Following ASCO 2024, Joshua K. Sabari, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the LAURA trial investigating osimertinib following definitive chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer with EGFR mutations.